Calcium channel blocker in patients with chronic kidney disease
Available in National Diet Library
Find on the publisher's website
NDL Digital Collections
Digital data available
Check on the publisher's website
DOI[10.1007/s10157-021-02153-1]to the data of the same series
Holdings of Libraries in Japan
This page shows libraries in Japan other than the National Diet Library that hold the material.
Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.
other
CiNii Research
Search ServiceDigitalYou can check the holdings of institutions and databases with which CiNii Research is linked at the site of CiNii Research.
Bibliographic Record
You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.
- Material Type
- 記事
- Author/Editor
- Shoko OhnoAkira IshiiMotoko Yanagita
- Publication, Distribution, etc.
- Publication Date
- 2021-11-08
- Publication Date (W3CDTF)
- 2021-11-08
- Periodical title
- Clinical and experimental nephrology : official publication of the Japanese Society of Nephrology
- No. or year of volume/issue
- 26(3)
- Volume
- 26(3)
- ISSN (Periodical Title)
- 1437-7799
- ISSN-L (Periodical Title)
- 1437-7799
- Text Language Code
- eng
- DOI
- 10.1007/s10157-021-02153-1
- Persistent ID (NDL)
- info:ndljp/pid/12289733
- Collection
- Collection (Materials For Handicapped People:1)
- Collection (particular)
- 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他
- Acquisition Basis
- オンライン資料収集制度
- Date Accepted (W3CDTF)
- 2022-05-23T15:55:37+09:00
- Date Captured (W3CDTF)
- 2022-05-16
- Format (IMT)
- application/pdf
- Access Restrictions
- 国立国会図書館内限定公開
- Service for the Digitized Contents Transmission Service
- 図書館・個人送信対象外
- Availability of remote photoduplication service
- 可
- Periodical Title (URI)
- Periodical Title (Persistent ID (NDL))
- info:ndljp/pid/12289732
- Data Provider (Database)
- 国立国会図書館 : 国立国会図書館デジタルコレクション
- Summary, etc.
- [Background] Chronic kidney disease (CKD) is involved in a progressive deterioration in renal function over the years and is now a global public health problem. Currently, reducing the number of patients progressing to end-stage renal failure is urgently necessary. Hypertension and CKD interact with each other, and good control of blood pressure (BP) can improve CKD patients’ prognosis. With the current global trend for more strict BP control, the importance of BP management and the need for medication to achieve this strict goal are increasing. Calcium channel blockers (CCBs), which target voltage-dependent calcium channels, are frequently used in combination with renin–angiotensin–aldosterone system inhibitors for CKD patients because of their strong BP-lowering properties and relatively few adverse side effects. Calcium channels have several subtypes, including L, N, T, P/Q, and R, and three types of CCBs, L-type CCBs, L-/T-type CCBs, and L-/N-type CCBs, that are available. Nowadays, the new functions and effects of the CCBs are being elucidated. [Conclusion] We should use different types of CCBs properly depending on their pharmacological effects, such as the strength of antihypertensive effects and the organ protection effects, taking into account the pathophysiology of the patients. In this article, the role and the use of CCBs in CKD patients are reviewed.
- DOI
- 10.1007/s10157-021-02153-1
- Access Restrictions
- インターネット公開
- Rights (production)
- © The Author(s) 2021This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
- Related Material (URI)
- References
- Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressureAssociation between the size of healthcare facilities and the intensity of hypertension therapy: a cross-sectional comparison of prescription data from insurance claims dataInhibition of N-type Ca[2+] channels ameliorates an imbalance in cardiac autonomic nerve activity and prevents lethal arrhythmias in mice with heart failure.The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global OutcomesMolecular and Functional Diversity of Voltage‐Gated Calcium ChannelsVasodilatory edema: A common side effect of antihypertensive therapyKDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney DiseaseAttenuation of renal fibrosis after unilateral ureteral obstruction in mice lacking the N-type calcium channelEffects of Vasopeptidase Inhibition on Renal Function and Tubuloglomerular Feedback in Spontaneously Hypertensive RatsClinical studies on pharmacological treatment of hypertension in JapanInvestigational calcium channel blockers for the treatment of hypertensionEfficacy and Safety of Combined vs. Single Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease: A Meta-AnalysisDeficiency of T-type Ca<sup>2+</sup> channels Ca<sub>v</sub>3.1 and Ca<sub>v</sub>3.2 has no effect on angiotensin II-induced hypertension but differential effect on plasma aldosterone in miceMultifunctional L/N- and L/T-type calcium channel blockers for kidney protectionEffect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesFunctional Importance of L- and P/Q-Type Voltage-Gated Calcium Channels in Human Renal VasculatureThe N- and L-Type Calcium Channel Blocker Cilnidipine Suppresses Renal Injury in Dahl Rats Fed a High-Sucrose Diet, an Experimental Model of Metabolic SyndromeComparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in ratsVascular Smooth Muscle Cells Express the α<sub>1A</sub>Subunit of a P-/Q-Type Voltage-Dependent Ca<sup>2+</sup>Channel, and It Is Functionally Important in Renal Afferent ArteriolesReno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysisCharacterization of three types of calcium channel in the luminal membrane of the distal nephronT-type voltage-gated calcium channels regulate the tone of mouse efferent arteriolesMechanistic View of Renal Protective Action of Calcium Channel BlockadePreserving renal function in adults with hypertension and diabetes: A consensus approachPedal edema—not all dihydropyridine calcium antagonists are created equalNew Role of P/Q-type Voltage-gated Calcium ChannelsA new-generation N/L-type calcium channel blocker leads to less activation of the renin–angiotensin system compared with conventional L type calcium channel blockerFunctional disorders of the sympathetic nervous system in mice lacking the α <sub>1B</sub> subunit (Ca <sub>v</sub> 2.2) of N-type calcium channelsRenin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical TrialsProgression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-AnalysisSystemic and glomerular hypertension and progression of chronic renal disease: The dilemma of nephrosclerosisA Randomized Trial of Intensive versus Standard Blood-Pressure ControlThe α<sub>1G</sub>-subunit of a voltage-dependent Ca<sup>2+</sup>channel is localized in rat distal nephron and collecting ductDifferent Effects of L/N-Type and L-Type Calcium Channel Blockers on the Renin-Angiotensin-Aldosterone System in SHR/IzmBenazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk PatientsDifferential Expression of T- and L-Type Voltage-Dependent Calcium Channels in Renal Resistance Vessels2020 International Society of Hypertension Global Hypertension Practice GuidelinesCa<sup>2+</sup>Channel Subtypes and Pharmacology in the KidneyTubular and cellular localization of the cardiac L-type calcium channel in rat kidneyRenal-Protective Effect of T- and L-Type Calcium Channel Blockers in Hypertensive Patients: An Amlodipine-to-Benidipine Changeover (ABC) StudyInhibitory Effect of Efonidipine on Aldosterone Synthesis and Secretion in Human Adrenocarcinoma (H295R) CellsStructure and Regulation of Voltage-Gated Ca<sup>2+</sup> ChannelsImpact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipineBenidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive ratsClinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomyCKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuriaTelmisartan, Ramipril, or Both in Patients at High Risk for Vascular EventsCilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyteCa2+ Channel α1B Subunit (CaV 2.2) Knockout Mouse Reveals a Predominant Role of N-Type Channels in the Sympathetic Regulation of the Circulatory SystemMolecular Basis for CA2+ Channel DiversityDominant Role of N-Type Ca <sup>2+</sup> Channels in Evoked Release of Norepinephrine from Sympathetic NeuronsCombined Angiotensin Inhibition for the Treatment of Diabetic NephropathyAntiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal diseaseDiscovery and Development of Calcium Channel BlockersNomenclature of Voltage-Gated Calcium ChannelsCilnidipine Attenuates Renal Nerve Stimulation-Induced Renal Vasoconstriction and Antinatriuresis in Anesthetized Dogs.Disparate Effects of Calcium Antagonists on Renal Microcirculation.Effects of the T/L-type Calcium Channel Blocker Benidipine on Albuminuria and Plasma Aldosterone ConcentrationEffects of L/N-Type Calcium Channel Antagonist, Cilnidipine on Progressive Renal Injuries in Dahl Salt-Sensitive RatsN-type Calcium Channel Inhibition With Cilnidipine Elicits Glomerular Podocyte Protection Independent of Sympathetic Nerve Inhibition
- Data Provider (Database)
- 国立情報学研究所 : CiNii Research
- Original Data Provider (Database)
- 学術機関リポジトリデータベース雑誌記事索引データベースCrossref科学研究費助成事業データベース科学研究費助成事業データベース
- Bibliographic ID (NDL)
- 12289733